亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 呋喃妥因CAS No. 67-20-9
呋喃妥因CAS No. 67-20-9
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 67-20-9
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
呋喃妥因
CAS No. 67-20-9
別名呋喃坦丁,呋喃坦啶,硝呋妥因,硝基呋喃妥因,
英文/拉丁名稱,Nitrofurantion,Furadantin,Furan,Furantoin,Macrodantin,Urantoin
化學名:1-[[(5-硝基-2-呋喃基)亞甲基]氨基]-2,4-咪唑烷二酮
熔點:270-272℃ 
分子式 C8H6N4O5  
分子量 238.16
熔點:270-272℃ 
標準:BP2005、EP5.0、USP27
含量:99%
性狀:本品為鮮黃色結晶性粉末,無臭,味苦,遇光色變深。
用途:呋喃妥因本品為合成抗菌藥,抗菌譜較廣,對大多數革蘭陽性菌及陰性菌均有抗菌作用,如金葡菌、大腸桿菌、白色葡萄球菌及化膿性鏈球菌等。臨床上用于敏感菌所致的泌尿系統感染,如腎盂腎炎、尿路感染、膀胱炎及前列腺炎等。
包裝:25ke/g/桶
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31231  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |